Ironwood Pharmaceuticals, Inc.

Cyclerion Therapeutics, Inc.

Tisento Therapeutics Inc.

Ara Mermerian

Takashi Nakai

Rajesh R Iyengar

Timothy Claude Barden

Paul A Renhowe

Glen Robert Rennie

Thomas Wai-Ho Lee

Joon Jung

G-Yoon Jamie Im

Karthik Iyer

Joel D Moore

Nicholas Robert Perl

Mark G Currie

James Edward Sheppeck

Colleen Hudson

Xiang Y Yu

Lei Jia

Kimberly Kafadar Long

James Jia

George Todd Milne

Charles Kim

Kevin Sprott

Angelika Fretzen

Jason Matthew Rohde

Jane Yang

Kim Tang

Peter Germano

John Jeffrey Talley

G Todd Milne

James Philip Pearson

Wilmin Bartolini

Bo Peng

Craig N Zimmerman

Barbara B Chen

Brian Cali

Yueh-Tyng Chien

Nicholas Perl

Wayne Schairer

Regina Graul

Regina Lundigran

Helen Cumberbatch

Regina Lundrigan

Paul Allen Renhowe

Mark Currie

Paul Allan Renhowe

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula I:

sGC stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts, pharmaceutical formulations comprising them as well as their phosphate ester prodrugs, and their uses alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or the upregulation of the NO pathway is desirable. The compounds are of Formula I.

Compounds of Formulae I' and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I). 

SGC stimulators

The present patent application discloses the compounds according to Formula (I) shown below, or pharmaceutically acceptable salts thereof wherein J, n, R, R, R, R, R, m and X as defined herein. 

Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: 

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, J, n, J, J, X, Z, Z, R, R, Y, R, o and W are as defined herein.

Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. 

The present disclosure relates to compounds useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment or prevention of various disorders. Compounds of the invention are described in Table 1.

FAAH inhibitors

Indole derivatives that are useful for treating pain, inflammation and other conditions are described. Certain of the compounds are benzyl derivatives and others are benzoyl derivatives. The compounds are substituted at least at the 3 position of the indole.

Indole compounds

Growing community of inventors

Waltham, MA, United States of America

Ara Mermerian